MARAVAI LIFESCIENCES HOLDINGS Business Summary

Maravai LifeSciences Holdings, Inc. (MRVI) operates as a critical provider of life science reagents and services, generating revenue primarily through the sale of proprietary products and specialized services to biopharmaceutical and diagnostic companies. The business is organized into two core segments: Nucleic Acid Production (NAP) and Biologics Safety Testing (BST). The NAP segment, which includes the industry-leading CleanCap® mRNA capping technology, focuses on the synthesis of highly modified nucleic acids and enzymes for vaccine and therapeutic development. The BST segment provides specialized analytical products and services, such as host cell protein (HCP) impurity testing, to ensure the safety and quality of biological drugs during manufacturing. Maravai competes directly with global life science giants and specialized firms including Thermo Fisher Scientific, Lonza, Charles River Laboratories, and Aldevron. Within this landscape, Maravai maintains a high-margin niche as a specialized leader in mRNA synthesis components and biologics impurity detection, positioning itself as an essential partner for next-generation genomic medicine. Founded in 2014 by industry veterans Carl Hull and Eric Tardif with backing from private equity firm GTCR, Maravai is currently led by Chief Executive Officer Bernd Brust, who was appointed in June 2025 to drive the company’s post-pandemic strategic pivot. The executive team includes Raj Asarpota as Executive Vice President and Chief Financial Officer, and Dr. Chanfeng Zhao, who serves as Senior Vice President and Chief Scientific Officer, bringing extensive expertise in nucleotide chemistry and synthetic genomics. The company’s board of directors is chaired by R. Andrew Eckert and includes co-founder Carl Hull as Executive Chairman, alongside representatives from GTCR, such as Constantine Mihas and Sean Cunningham. This leadership team combines decades of experience from major life science entities like Life Technologies, GE Healthcare, and Illumina, providing the technical and operational pedigree required to navigate the complex regulatory and manufacturing requirements of the biotechnology sector.